HMGN (Hemagen Diagnostics) OCF Margin %: -5.82% (As of Sep. 2012)


What is Hemagen Diagnostics OCF Margin %?

Hemagen Diagnostics HMGN +766.67% OCF Margin % is -5.82% as of Sep. 2012.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Hemagen Diagnostics's Cash Flow from Operations for the three months ended in Sep. 2012 was $-0.05 Mil. Hemagen Diagnostics's Revenue for the three months ended in Sep. 2012 was $0.88 Mil. Therefore, Hemagen Diagnostics's OCF Margin % for the quarter that ended in Sep. 2012 was -5.82%.

As of today, Hemagen Diagnostics's current OCF Yield % is -897.50%.

The historical rank and industry rank for Hemagen Diagnostics's OCF Margin % or its related term are showing as below:

HMGN' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -8.88

HMGN's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -66.52 vs HMGN: -8.88

Hemagen Diagnostics OCF Margin % Related Terms

Hemagen Diagnostics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics OCF Margin % Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.16 0.31 -3.51 -6.56 -8.88

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 -18.79 -10.53 1.79 -5.82

HMGN vs OBMP, NSPX, ATRX: OCF Margin % Comparison

For the Biotechnology subindustry, Hemagen Diagnostics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemagen Diagnostics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's OCF Margin % falls into.


Hemagen Diagnostics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Hemagen Diagnostics's OCF Margin for the fiscal year that ended in Sep. 2012 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2012 )/Revenue (A: Sep. 2012 )
=-0.359/4.042
=-8.88 %

Hemagen Diagnostics's OCF Margin for the quarter that ended in Sep. 2012 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2012 )/Revenue (Q: Sep. 2012 )
=-0.051/0.876
=-5.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -5.82% mean?
Hemagen Diagnostics (HMGN) has a OCF Margin % of -5.82% as of Sep. 2012. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' OCF Margin % too high?
Hemagen Diagnostics' current OCF Margin % is -5.82%.
How does Hemagen Diagnostics' OCF Margin % compare to OBMP and NSPX?
Hemagen Diagnostics' OCF Margin % of -5.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hemagen Diagnostics and its competitors. Hemagen Diagnostics's current OCF Margin % is -5.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current OCF Margin % of -5.82%. The current OCF Margin % is -5.82%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current OCF Margin % is -5.82% as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.